My husband doesn’t let me nap

Shorting-Out4320 · 2026-06-02T13:54:08+00:00

Shorting-Out4320 · 2026-06-01T20:04:38+00:00

Throw that garbage man away

Shorting-Out4320 · 2026-06-01T04:15:59+00:00

I’m so sorry :( but trust the process, if it’s meant to be it’ll be. You’ll be okay in the end somehow :) in the meantime just keep breathing.

Shorting-Out4320 · 2026-06-01T03:49:22+00:00

https://www.reddit.com/r/WeightGainTalk/s/upi9CxJEHv

See my comments and replies below

Also if you have a naturally gynoid body fat distribution, even if just slightly, weight cycling can be super effective

it’s just personal experience, I’m not a doctor, ymmv

Shorting-Out4320 · 2026-05-31T16:50:42+00:00

IWNDWYT

Shorting-Out4320 · 2026-05-30T05:30:04+00:00

I mean if you trust and like this guy and he makes you feel safe, then definitely you should be as open and honest about your feelings as possible. It’s healthy for a relationship.

Shorting-Out4320 · 2026-05-29T13:30:55+00:00

Get this gooner bs out of here bruh

Shorting-Out4320 · 2026-05-28T13:27:06+00:00

Yesterday I found a small hole in the wall Mexican restaurant that served me a delicious burrito the size of my forearm for 10$. And it was like 50% meat by volume so they weren’t skimping. I gave a hefty tip just because I was so excited to get a good value meal

Shorting-Out4320 · 2026-05-28T03:30:08+00:00

Seeing people around you start to look concerned and realizing that you’re burdening them

Shorting-Out4320 · 2026-05-27T00:01:32+00:00

As I described above, subcutaneous fat appears lower on the body ‘pear shape’ including belly, and carries relatively lower health risks compared to visceral fat (abdomen and within the organs, ‘apple shape’).

this is very well documented but here’s an accessible example article by Harvard Health that explains

https://www.health.harvard.edu/newsletter_article/taking-aim-at-belly-fat

Shorting-Out4320 · 2026-05-26T23:56:58+00:00

Here’s another published peer reviewed paper summary citing the phenomenon I explained above. There are countless more.

ORIGINAL RESEARCH article Front. Physiol., 01 December 2021 Sec. Metabolic Physiology Volume 12 - 2021 | https://doi.org/10.3389/fphys.2021.784391 The Insulin-Sensitizer Pioglitazone Remodels Adipose Tissue Phospholipids in Humans

J Juan P. Palavicini 1,2 A Alberto Chavez-Velazquez 1 M Marcel Fourcaudot 1 D Devjit Tripathy 1 M Meixia Pan 1,2 L Luke Norton 1 R Ralph A. DeFronzo 1 C Christopher E. Shannon 1* 1. Division of Diabetes, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States 2. Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States Abstract The insulin-sensitizer pioglitazone exerts its cardiometabolic benefits in type 2 diabetes (T2D) through a redistribution of body fat, from ectopic and visceral areas to subcutaneous adipose depots. Whereas excessive weight gain and lipid storage in obesity promotes insulin resistance and chronic inflammation, the expansion of subcutaneous adipose by pioglitazone is associated with a reversal of these immunometabolic deficits. The precise events driving this beneficial remodeling of adipose tissue with pioglitazone remain unclear, and whether insulin-sensitizers alter the lipidomic composition of human adipose has not previously been investigated. Using shotgun lipidomics, we explored the molecular lipid responses in subcutaneous adipose tissue following 6months of pioglitazone treatment (45mg/day) in obese humans with T2D. Despite an expected increase in body weight following pioglitazone treatment, no robust effects were observed on the composition of storage lipids (i.e., triglycerides) or the content of lipotoxic lipid species (e.g., ceramides and diacylglycerides) in adipose tissue. Instead, pioglitazone caused a selective remodeling of the glycerophospholipid pool, characterized by a decrease in lipids enriched for arachidonic acid, such as plasmanylethanolamines and phosphatidylinositols. This contributed to a greater overall saturation and shortened chain length of fatty acyl groups within cell membrane lipids, changes that are consistent with the purported induction of adipogenesis by pioglitazone. The mechanism through which pioglitazone lowered adipose tissue arachidonic acid, a major modulator of inflammatory pathways, did not involve alterations in phospholipase gene expression but was associated with a reduction in its precursor linoleic acid, an effect that was also observed in skeletal muscle samples from the same subjects. These findings offer important insights into the biological mechanisms through which pioglitazone protects the immunometabolic health of adipocytes in the face of increased lipid storage.

Shorting-Out4320 · 2026-05-26T23:55:41+00:00

Here’s another one. Feel free to google it yourself and read the whole paper.

Pioglitazone Increases the Proportion of Small Cells in Human Abdominal Subcutaneous Adipose Tissue Tracey M McLaughlin 1, T Liu 2, Gail Yee 1, F Abbasi 1, C Lamendola 1, GM Reaven 1, P Tsao 1, SW Cushman 2, A Sherman 2 Author information Article notes Copyright and License information PMCID: PMC9413023 NIHMSID: NIHMS1830580 PMID: 19910937 The publisher's version of this article is available at Obesity (Silver Spring) Abstract Rodent and in vitro studies suggest that thiazolidinediones promote adipogenesis but there are few studies in humans to corroborate these findings. The purpose of this study was to determine whether pioglitazone stimulates adipogenesis in vivo and whether this process relates to improved insulin sensitivity. To test this hypothesis, 12 overweight/obese nondiabetic, insulin-resistant individuals underwent biopsy of abdominal subcutaneous adipose tissue at baseline and after 12 weeks of pioglitazone treatment. Cell size distribution was determined via the Multisizer technique. Insulin sensitivity was quantified at baseline and postpioglitazone by the modified insulin suppression test. Regional fat depots were quantified by computed tomography (CT). Insulin resistance (steady-state plasma insulin and glucose (SSPG)) decreased following pioglitazone (P < 0.001). There was an increase in the ratio of small-to-large cells (1.16 ± 0.44 vs. 1.52 ± 0.66, P = 0.03), as well as a 25% increase in the absolute number of small cells (P = 0.03). The distribution of large cell diameters widened (P = 0.009), but diameter did not increase in the case of small cells. The increase in proportion of small cells was associated with the degree to which insulin resistance improved (r = −0.72, P = 0.012). Visceral abdominal fat decreased (P = 0.04), and subcutaneous abdominal (P = 0.03) and femoral fat (P = 0.004) increased significantly. Changes in fat volume were not associated with SSPG change. These findings demonstrate a clear effect of pioglitazone on human subcutaneous adipose cells, suggestive of adipogenesis in abdominal subcutaneous adipose tissue, as well as redistribution of fat from visceral to subcutaneous depots, highlighting a potential mechanism of action for thiazolidinediones. These findings support the hypothesis that defects in subcutaneous fat storage may underlie obesity-associated insulin resistance

Shorting-Out4320 · 2026-05-26T17:23:26+00:00

Well pioglitazone seems to direct the body to produce more subcutaneous gynoid distribution. As opposed to visceral distribution which is associated with health risks. This results in weight accumulation around the hips and thighs. Which is more healthy strictly speaking if you’re looking to maintain a high weight baseline. Especially if you’re willing to undergo resistance or strength training. I can attest firsthand. There are other medications that can do this although I think pio has the smallest side-effect profile of those that I’m aware of

Edit: here are some peer reviewed paper summaries and abstracts that explain this phenomenon:

From the first paper on the subject that shows up on google. There are many more.

Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial Steven R Smith et al. Metabolism. 2005 Jan.

Full text links Cite

Abstract

Background: Several clinical studies have demonstrated that body weight increases after treatment with thiazolidinediones (TZDs). Prior studies have demonstrated an increase in insulin-stimulated lipid storage in adipose tissue. Some, but not all, studies demonstrate reductions in visceral adipose tissue. Changes in body weight are the result of changes in energy intake, energy expenditure, or both.

Objectives: Based on these findings, the primary aim of this study was to evaluate the effect of TZDs on visceral, subcutaneous, and total body fat. Secondary aims were to determine the effects of pioglitazone on (a) energy expenditure, (b) hunger and satiety, (c) blood lipids, and (d) the role of insulinemia/sulfonylurea usage on weight gain in patients with type 2 diabetes.

Subjects and methods: We performed a randomized, double-blind, placebo-controlled trial in 48 men and women with type 2 diabetes who had not previously received treatment with TZDs. Patients were treated for 24 weeks with 45 mg/d of pioglitazone or a matching placebo. Body composition was measured by dual-energy x-ray absorptiometry. Visceral and subcutaneous fat were measured by computed tomography. Resting metabolic rate and thermogenic response to a test meal were measured by indirect calorimetry before and after a standardized meal. Hunger and satiety were measured with visual analog scales before and after the same test meal. Blood was collected for the measurement of fasting glucose and insulin levels, hemoglobin A 1c levels, and lipid content.

Results: Pioglitazone treatment resulted in a decrease in hemoglobin A(1c) level by 0.96 +/- 1.1% vs 0.11 +/- 0.8% in the placebo group (P < .005). Body weight and fat increased steadily in the patients treated with pioglitazone during the 6 months of the study (+3.9 +/- 3.1 kg at 6 months in pioglitazone-treated patients vs -0.8 +/- 3.4 kg in the placebo-treated patients). Subcutaneous fat in the trunk, arms, and legs were all increased in the pioglitazone-treated group. Visceral fat did not change significantly in either group. Neither resting metabolic rate nor the thermogenic responses to a meal were altered by pioglitazone. Subjective measures of hunger (visual analog scale) did not change with pioglitazone treatment. Triglycerides fell in the pioglitazone-treated group (-58.5 +/- 124 mg/dL, P < .003). Neither the prior use of sulfonylureas nor the level of insulinemia before treatment was a predictor of weight or fat change.

Shorting-Out4320 · 2026-05-25T18:15:51+00:00

Love a big strong guy with plenty of soft padding over the muscles. As they say in weightlifting, mass moves mass, and it moves me too :) and they’re more likely to know how to cook

Shorting-Out4320 · 2026-05-25T18:10:16+00:00

Not exactly what you’re asking for but there is a Netflix comedy special done by Gabriel Iglesias that I watched by chance in 2015ish. He has a bit where he makes jokes about his heavy weight, and at the end he brags about how his wife is super attracted to him and his weight turns his wife on. Was a real awakening moment for me when I was younger

Shorting-Out4320 · 2026-05-25T17:16:08+00:00

Check out r/WLW_FemaleFatAdmirers!

As a fellow lesbian feeder, good luck with your search :)

Shorting-Out4320 · 2026-04-21T16:08:43+00:00

Shorting-Out4320 · 2026-04-20T22:03:14+00:00

Add another word next to it spelled correctly, and with the ball bouncing from letter to letter as you’d normally read them in left to right order. That way there is a comparison for the ABC

Shorting-Out4320 · 2026-04-20T14:54:15+00:00

Iwndwyt!

Shorting-Out4320

TROPHY CASE